Archive · 9 Jun 2025
Balaxi Pharmaceuticals Stock Jumps on Expansion Plans, Financial Results
Balaxi Pharmaceuticals, a small-cap stock, saw its share price increase after the company shared its plans to grow.
They want to enter new countries and build a new factory to make their own medicines.
The company's profits for the year were good overall, but costs went up, affecting some areas of profit.
The company has also seen recent improvements after a tough year in the stock market.
Balaxi Pharmaceuticals' stock surged over 10% on Monday, June 9, reaching ₹57.5.
The jump was driven by the company's announcement of its expansion plans and FY25 financial results.
Balaxi plans to expand into new markets in Latin America, Southeast Asia, and the CIS.
The company is establishing a pharmaceutical formulation manufacturing facility in Hyderabad.
For FY25, Balaxi reported a net profit of ₹25 crore, but EBITDA fell due to rising costs.
- Who
- Balaxi Pharmaceuticals, a small-cap company.
- What
- Balaxi Pharmaceuticals' stock price increased significantly.
- When
- June 9, following the announcement of its strategic expansion roadmap and FY25 financial results.
- Where
- The stock traded on the market; the new manufacturing facility is in Jadcherla, Hyderabad.
- Why
- Driven by expansion plans, backward integration, and positive financial results.
- Intra-day High
- ₹57.5
- Intra-day Jump
- 10.7%
- FY25 Net Profit
- ₹25 crore
- Annual Revenue (FY25)
- ₹292.5 crore
- EBITDA (FY25)
- ₹33.5 crore
- Annual Revenue Growth (FY25)
- 21%
- Products across 7 countries
- 915